Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden · Delayed Price · Currency is SEK 5.33
+0.06 (1.14%)
Jun 12, 2026, 5:29 PM CET
Egetis Therapeutics AB Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Egetis Therapeutics AB stock has a consensus rating of "Buy" and an average price target of kr 8.20. The average 1-year stock price forecast is 53.85% higher than the current stock price, while the lowest is kr 1.60 (-69.98%) and the highest is kr 12.00 (+125.14%).
Price Target: kr 8.20 (+53.85%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Egetis Therapeutics AB stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Financial Forecast
Revenue This Year
554.58M
from 62.40M
Increased by 788.75%
Revenue Next Year
411.82M
from 554.58M
Decreased by -25.74%
EPS This Year
0.46
from -0.90
EPS Next Year
-0.20
from 0.46
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is SEK.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 996.6M | ||
| Avg | 554.6M | ||
| Low | 102.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1,497.1% | ||
| Avg | 788.8% | ||
| Low | 63.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | 0.46 | ||
| Low | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |